5709 related articles for article (PubMed ID: 2554787)
21. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
[TBL] [Abstract][Full Text] [Related]
22. Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype.
Albino AP; Sozzi G; Nanus DM; Jhanwar SC; Houghton AN
Oncogene; 1992 Nov; 7(11):2315-21. PubMed ID: 1437153
[TBL] [Abstract][Full Text] [Related]
23. Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression.
Bianchini F; Massi D; Marconi C; Franchi A; Baroni G; Santucci M; Mannini A; Mugnai G; Calorini L
Prostaglandins Other Lipid Mediat; 2007 Jun; 83(4):320-8. PubMed ID: 17499752
[TBL] [Abstract][Full Text] [Related]
24. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression.
Jiang H; Lin JJ; Su ZZ; Goldstein NI; Fisher PB
Oncogene; 1995 Dec; 11(12):2477-86. PubMed ID: 8545104
[TBL] [Abstract][Full Text] [Related]
25. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.
Huang S; Luca M; Gutman M; McConkey DJ; Langley KE; Lyman SD; Bar-Eli M
Oncogene; 1996 Dec; 13(11):2339-47. PubMed ID: 8957075
[TBL] [Abstract][Full Text] [Related]
26. Primary melanoma cells of the vertical growth phase: similarities to metastatic cells.
Herlyn M; Balaban G; Bennicelli J; Guerry D; Halaban R; Herlyn D; Elder DE; Maul GG; Steplewski Z; Nowell PC
J Natl Cancer Inst; 1985 Feb; 74(2):283-9. PubMed ID: 3856042
[TBL] [Abstract][Full Text] [Related]
27. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
de Vries TJ; Quax PH; Denijn M; Verrijp KN; Verheijen JH; Verspaget HW; Weidle UH; Ruiter DJ; van Muijen GN
Am J Pathol; 1994 Jan; 144(1):70-81. PubMed ID: 8291613
[TBL] [Abstract][Full Text] [Related]
28. Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma.
Guerry D; Alexander MA; Elder DE; Herlyn MF
J Immunol; 1987 Jul; 139(1):305-12. PubMed ID: 3108402
[TBL] [Abstract][Full Text] [Related]
29. Multiple complementary transcripts of pCMa1, a novel gene located at chromosome 11p15.1-2, and melanocytic cell transformation.
Meije CB; Das PK; Jans MM; Hau C; van der Wal AC; Alders M; Hakvoort TB; Weidle UH; Lamers WH; Swart GW
J Pathol; 2002 Aug; 197(5):668-76. PubMed ID: 12210088
[TBL] [Abstract][Full Text] [Related]
30. Expression of thyrotropin-releasing hormone by human melanoma and nevi.
Ellerhorst JA; Naderi AA; Johnson MK; Pelletier P; Prieto VG; Diwan AH; Johnson MM; Gunn DC; Yekell S; Grimm EA
Clin Cancer Res; 2004 Aug; 10(16):5531-6. PubMed ID: 15328193
[TBL] [Abstract][Full Text] [Related]
31. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
Wang Y; Becker D
Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
[TBL] [Abstract][Full Text] [Related]
33. The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells.
Lebedeva IV; Su ZZ; Chang Y; Kitada S; Reed JC; Fisher PB
Oncogene; 2002 Jan; 21(5):708-18. PubMed ID: 11850799
[TBL] [Abstract][Full Text] [Related]
34. Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells.
Herlyn M; Guerry D; Koprowski H
J Immunol; 1985 Jun; 134(6):4226-30. PubMed ID: 2985706
[TBL] [Abstract][Full Text] [Related]
35. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma.
Clark WH; Elder DE; Guerry D; Epstein MN; Greene MH; Van Horn M
Hum Pathol; 1984 Dec; 15(12):1147-65. PubMed ID: 6500548
[TBL] [Abstract][Full Text] [Related]
36. Survivin protein in UVB induced apoptosis of melanoma cells and in melanoma progression.
Zhang H
Oncol Rep; 2005 Jun; 13(6):1121-6. PubMed ID: 15870931
[TBL] [Abstract][Full Text] [Related]
37. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Shapiro RL; Duquette JG; Roses DF; Nunes I; Harris MN; Kamino H; Wilson EL; Rifkin DB
Cancer Res; 1996 Aug; 56(15):3597-604. PubMed ID: 8758932
[TBL] [Abstract][Full Text] [Related]
38. Functional evidence of novel tumor suppressor genes for cutaneous malignant melanoma.
Parris CN; Harris JD; Griffin DK; Cuthbert AP; Silver AJ; Newbold RF
Cancer Res; 1999 Feb; 59(3):516-20. PubMed ID: 9973191
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment.
Seftor EA; Brown KM; Chin L; Kirschmann DA; Wheaton WW; Protopopov A; Feng B; Balagurunathan Y; Trent JM; Nickoloff BJ; Seftor RE; Hendrix MJ
Cancer Res; 2005 Nov; 65(22):10164-9. PubMed ID: 16288000
[TBL] [Abstract][Full Text] [Related]
40. Association between sialyl Lewis(a) expression and tumor progression in melanoma.
Kageshita T; Hirai S; Kimura T; Hanai N; Ohta S; Ono T
Cancer Res; 1995 Apr; 55(8):1748-51. PubMed ID: 7712483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]